Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support
NCT ID: NCT03922451
Last Updated: 2022-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
4 participants
OBSERVATIONAL
2019-08-27
2022-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of a Loading Dose of Vancomycin in Pediatric Dosing
NCT01290237
Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)
NCT02266706
Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)
NCT06426836
Pharmacokinetics of Piperacillin and Meropenem in ICU Patients
NCT05134298
Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium
NCT02288429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pediatric patients supported on ECMO
piperacillin-tazobactam
Administered for infection treatment or prophylaxis per hospital protocol
Cefazolin
Administered for infection treatment or prophylaxis per hospital protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
piperacillin-tazobactam
Administered for infection treatment or prophylaxis per hospital protocol
Cefazolin
Administered for infection treatment or prophylaxis per hospital protocol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* receive piperacillin-tazobactam or cefazolin as part of routine care or infection management
Exclusion Criteria
* No Consent provided
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Katie Moynihan
Cardiac Intensivist
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Boston Children's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-P00030970
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.